C07D277/48

CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF

Provided herein are compounds useful as inhibitors of CBX. Also described are pharmaceutical compositions and medical uses of these compounds.

HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS
20240101546 · 2024-03-28 ·

Provided herein are heteroaryl-acetylene compounds, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of GPX4-mediated disorders, diseases, or conditions.

##STR00001##

Aryl hydrocarbon receptor (AHR) agonists and uses thereof

The present invention provides AHR agonists, compositions thereof, and methods of using the same.

Aryl hydrocarbon receptor (AHR) agonists and uses thereof

The present invention provides AHR agonists, compositions thereof, and methods of using the same.

Analogs of proxisome proliferator activated receptor (PPAR) agonists and methods of using the same

Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

CDK19-Selective Inhibitors, and Methods of Use Thereof

Provided herein are compounds or pharmaceutically acceptable salts thereof, having a structure of formula (I): wherein substituents are as described herein. Also provided is a pharmaceutical composition comprising a compound or pharmaceutically acceptable salt having a structure of formula (I). Further provided are a method of inhibiting cyclin dependent kinase 19 (CDK19) a method of treating cancer (e.g., breast cancer) with the disclosed compounds.

##STR00001##

CDK19-Selective Inhibitors, and Methods of Use Thereof

Provided herein are compounds or pharmaceutically acceptable salts thereof, having a structure of formula (I): wherein substituents are as described herein. Also provided is a pharmaceutical composition comprising a compound or pharmaceutically acceptable salt having a structure of formula (I). Further provided are a method of inhibiting cyclin dependent kinase 19 (CDK19) a method of treating cancer (e.g., breast cancer) with the disclosed compounds.

##STR00001##

Methods of chemotype evolution

Herein is described a method to rapidly screen a large chemical space for a compound that binds to a target protein through an iterative fragment assembly approach that can be performed at low reagent cost and without requiring purification of the assembled product. The method employs a library of test ligands each of which comprise a bait molecule, which is known from prior art or prior screening to have some intrinsic affinity for the target protein, and a test moiety.

CHEMICAL SYNTHESIS

Herein are described methods of chemical synthesis.

CHEMICAL SYNTHESIS

Herein are described methods of chemical synthesis.